Crenigacestat is under clinical development by Eli Lilly and Co and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Crenigacestat’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 17 Mar 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 17 Mar 2021 decreased Crenigacestat’s Phase Transition Success Rate (PTSR) for Colon Cancer, and decreased LoA and PTSR for Soft Tissue Sarcoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Crenigacestat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Crenigacestat overview

Crenigacestat (LY-3039478) is under development for the treatment of adenoid cystic carcinoma, soft tissue sarcoma, metastatic colon cancer, metastatic triple negative breast cancer, metastatic hepatocellular carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, leiomyosarcoma, natural killer (NK) cell neoplasm, glioblastoma, B-cell lymphoma, gastrointestinal stromal tumours (GIST), T-cell lymphoblastic lymphoma (T-LBL) and refractory/relapsed multiple myeloma. The drug candidate is a new chemical entity (NCE). It is administered orally and intravenously. It targets Notch 1 receptor, and gamma-secretase. It was under development for the treatment of  T-cell acute lymphoblastic leukemia (T-ALL).

Eli Lilly and Co overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Quick View Crenigacestat LOA Data

Report Segments
  • Innovator
Drug Name
  • Crenigacestat
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.